Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 4 de 4
Filter
Add more filters











Database
Language
Publication year range
1.
Eur J Cancer ; 48(7): 1108-15, 2012 May.
Article in English | MEDLINE | ID: mdl-22446020

ABSTRACT

BACKGROUND: KRAS testing is mandatory if anti-EGFR therapy is considered in patients with metastatic colorectal cancer (CRC). In addition, BRAF mutations seem to be an important negative prognostic factor. The aim of this study is to establish the concordance of KRAS and BRAF mutational status in paired biopsy and resection specimens of primary CRC using several analytic methods. METHODS: DNA was extracted from paraffin blocks of 126 CRC patients. KRAS codon 12/13 and BRAF V600E mutational status was assessed using high resolution melting (HRM), direct sequencing (DS) of the HRM polymerase chain reaction (PCR) product. In addition, the Therascreen Amplification Refractory Mutation System (ARMS)-Scorpion KRAS assay and BRAF pyrosequencing were employed; both assays claim to require less tumour cells in comparison with DS. RESULTS: KRAS and BRAF were found to be mutually exclusive. Mutation frequencies were 33.9% for KRAS, and for BRAF 19.0%, respectively. Concordance of KRAS mutational status between biopsy and resection specimens was 97.4% (ARMS), 98.4% (DS) and 99.2% (HRM), respectively. For BRAF concordance was 98.4% (Pyro, DS) and 99.2% (HRM). CONCLUSIONS: KRAS and BRAF mutational status of endoscopic biopsies and resection specimens of CRC showed a >95% concordance. Endoscopic biopsies can be confidently used for molecular analysis.


Subject(s)
Adenocarcinoma/genetics , Colorectal Neoplasms/genetics , Genes, ras , Mutation , Proto-Oncogene Proteins B-raf/genetics , Adenocarcinoma/surgery , Aged , Biopsy , Colorectal Neoplasms/surgery , Endoscopy , Female , Humans , Male
2.
J Clin Pathol ; 56(1): 31-5, 2003 Jan.
Article in English | MEDLINE | ID: mdl-12499429

ABSTRACT

AIM: To examine whether the detection of either telomerase and its components or high risk human papillomavirus (HPV) are of value in predicting the presence of cervical intraepithelial neoplasia (CIN) grade II/III in women referred because of cervical cytology reports showing at most moderate dyskaryosis. METHODS: Cervical scrapings of 50 women referred with cytological borderline, mild, or moderate dyskaryosis were analysed. Telomerase activity was assessed by a commercially available telomere repeat amplification protocol assay and its components human telomerase RNA (hTR) and human telomerase reverse transcriptase (hTERT) were assessed by reverse transcriptase polymerase chain reaction (PCR). HPV was detected by GP5+/6+ PCR enzyme immunosassay. Histological findings on colposcopy guided biopsies or excised cervical tissue were regarded as the final pathological diagnosis. The sensitivity and specificity for detecting CIN II/III were calculated. RESULTS: Twenty eight women were diagnosed with CIN II/III. Telomerase activity was detected in none, hTR in 88%, hTERT in 23%, and high risk HPV was detected in 79% of these women. As a diagnostic test none of the described analyses combined a sensitivity of at least 90% with a specificity >or= 90%. Despite the small numbers, calculation of the 95% confidence intervals excluded a combined sensitivity and specificity of at least 90% for all of the evaluated parameters. CONCLUSIONS: Neither detection of telomerase or its components, nor detection of high risk HPV seem suitable for the triage of women with borderline, mild, and moderate cytological dyskaryosis.


Subject(s)
Biomarkers, Tumor/analysis , Papillomaviridae/isolation & purification , Telomerase/analysis , Uterine Cervical Dysplasia/diagnosis , Uterine Cervical Neoplasms/diagnosis , Adult , DNA-Binding Proteins , Female , Humans , Middle Aged , Precancerous Conditions/enzymology , Precancerous Conditions/virology , Predictive Value of Tests , RNA/analysis , Sensitivity and Specificity , Triage/methods , Uterine Cervical Dysplasia/enzymology , Uterine Cervical Dysplasia/virology , Uterine Cervical Neoplasms/enzymology , Uterine Cervical Neoplasms/virology , Vaginal Smears/methods
3.
Int J Cancer ; 91(5): 658-64, 2001 Mar 01.
Article in English | MEDLINE | ID: mdl-11267977

ABSTRACT

We investigated, in cervical cancer, the relation between telomerase activity, telomerase RNA (hTR) and mRNA of the catalytic subunit of telomerase, hTERT, with "classic" clinicopathological factors as well as survival. Frozen specimens were obtained from 107 consecutive patients with cervical cancer, treated with surgery or radiotherapy with or without chemotherapy. Telomerase activity was determined with fluorescence-based TRAP and hTR and hTERT with semi-quantitative RT-PCR. Eight normal cervical specimens served as controls. Analysis of prognostic factors and survival was limited to early-stage patients, treated primarily with radical hysterectomy. Telomerase activity was not detected in normal cervices and was present in 85 of 107 (79%) cervical cancers (p < 0.001). hTR was detected in all normal cervices and cervical cancers, while hTERT mRNA was detected in 1 of 8 (13%) normal cervices and in 83 of 104 (80%) cervical cancers (p < 0.001). In contrast to semi-quantitative hTR expression levels, semi-quantitative hTERT mRNA levels were related to telomerase activity levels (p < 0.01). In all patients, telomerase activity levels were related to differentiation grade (p < 0.05) but not to stage and histotype. In early-stage patients, telomerase activity, hTR and hTERT were not related to tumor volume, vascular invasion or presence of metastatic lymph nodes. Tumor volume, vascular invasion and presence of metastatic lymph nodes were related to (progression-free) survival, while telomerase activity and its subunits were not. Frequent up-regulation of telomerase activity and hTERT mRNA is especially observed in cervical cancers, while hTR is also detected in normal cervices. Telomerase is not applicable as a prognostic factor in early-stage cervical cancer patients.


Subject(s)
Prognosis , RNA , Telomerase/biosynthesis , Uterine Cervical Neoplasms/enzymology , Uterine Cervical Neoplasms/mortality , Cervix Uteri/enzymology , Cohort Studies , DNA, Complementary/metabolism , DNA-Binding Proteins , Disease-Free Survival , Female , Humans , Hysterectomy , Lymphatic Metastasis , RNA, Messenger/biosynthesis , RNA, Messenger/metabolism , Reverse Transcriptase Polymerase Chain Reaction , Treatment Outcome , Up-Regulation , Uterine Cervical Neoplasms/diagnosis , Uterine Cervical Neoplasms/therapy
4.
Br J Cancer ; 74(4): 502-7, 1996 Aug.
Article in English | MEDLINE | ID: mdl-8761362

ABSTRACT

A panel of doxorubicin-resistant sublines of the human small-cell lung carcinoma cell line GLC4 displays decreasing DNA topoisomerase II alpha (TopoII alpha) mRNA levels with increasing resistance. In the present study we describe how this decrease may be regulated. No significant differences in TopoII alpha mRNA stability or gene arrangement were found, using mRNA slot-blotting and Southern blotting, in the most resistant cell line compared with the parental cell line. To investigate if TopoII alpha gene copy loss contributed to the mRNA decrease, fluorescence in situ hybridisation using a TopoII alpha-specific probe was performed. During doxorubicin resistance development, the composition of the population in each cell line shifted with increasing resistance, from a population in which most cells contain three TopoII alpha gene copies (GLC4) to a population in which most cells contain only two copies. A partial revertant of the most resistant cell line displayed a shift back to the original situation. We conclude that the TopoII alpha gene copy number decrease per cell line is in good agreement with the decreased TopoII alpha mRNA and protein levels, and TopoII activity levels in these cell lines which were described previously.


Subject(s)
Carcinoma, Small Cell/genetics , DNA Topoisomerases, Type II/genetics , Doxorubicin/toxicity , Drug Resistance, Neoplasm/genetics , Lung Neoplasms/genetics , Blotting, Southern , Carcinoma, Small Cell/enzymology , Cell Line , DNA Probes , DNA Topoisomerases, Type II/biosynthesis , Dactinomycin/pharmacology , Gene Rearrangement , Genes, myc/drug effects , Humans , In Situ Hybridization, Fluorescence , Karyotyping , Lung Neoplasms/enzymology , Proto-Oncogene Proteins c-myc/biosynthesis , RNA, Messenger/analysis , RNA, Messenger/biosynthesis , Transcription, Genetic/drug effects , Tumor Cells, Cultured
SELECTION OF CITATIONS
SEARCH DETAIL